Following a limited submission
AWMSG advice |
|
| Status: Recommended | |
Budesonide (Jorveza®) orodispersible tablets are recommended for use within NHS Wales for maintaining remission of eosinophilic oesophagitis in adults. This recommendation is interim to the publication of NICE Technology Appraisal ID6486. |
|
Medicine details |
|
| Medicine name | budesonide (Jorveza®) |
| Formulation | 0.5 mg and 1 mg orodispersible tablet |
| Reference number | 4507 |
| Indication | For maintaining remission of eosinophilic oesophagitis in adults |
| Company | Dr Falk Pharma UK Ltd |
| BNF chapter | Gastro-intestinal system |
| Assessment type | Limited |
| Status | Recommended |
| Scrutiny Panel meeting date | 03/11/2025 |
| LOWMAG meeting date | 15/04/2026 |
| AWMSG meeting date | 20/05/2025 |
| Date of issue | 26/05/2026 |